<DOC>
	<DOCNO>NCT02330952</DOCNO>
	<brief_summary>Primary objective : The aim study determine efficacy safety five day oral corticosteroid ( 40 mg / day ) treatment acute exacerbation COPD ( AECOPD ) outpatient .</brief_summary>
	<brief_title>Efficacy Corticosteroids Treat Outpatients With Acute Exacerbations COPD</brief_title>
	<detailed_description>COPD major grow public health issue . The vast majority case care primary care , follow-up stable state treatment exacerbation , represent major event natural history disease . Systemic corticosteroid treatment often propose exacerbation treatment , although guideline area heterogeneous regard precise indication treatment . The late data literature , seem show efficacy oral corticosteroid involve patient see hospital . General practitioner need evidence-base information choose whether give oral corticosteroid patient ; therefore important good define benefit-risk ratio precise indication oral corticosteroid part care COPD exacerbation . The investigator build randomize double-blind control trial answer question .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Adults age 40 year Smoking ≥ 10 packyears Patients suspect acute exacerbation COPD Patients give write informed consent participate study Known suspect chronic respiratory disease COPD ( asthma , bronchiectasis ... ) Suspected pneumonia pulmonary oedema Decision hospitalization Patients take oral corticosteroid run stop less week inclusion Pathology compromise compliance Fever unexplained current AECOPD Uncontrolled hypertension Uncontrolled diabetes Deep infectious disease History ancient untreated tuberculosis Untreated peptic ulcer Unhealed wound Ulcerative Colitis Allergy steroids Any severe uncontrolled infection specify therapeutic indication SPC ( Summary Product Characteristics ) Hepatitis , acute genital herpes , varicella , acute zoster Live attenuate vaccine , recent plan Psychoses control treatment Hypersensitivity prednisone excipients Cortancyl® , include lactose intolerance Patients already include BECOMEG Patients move within 8 week inclusion study Patients affiliate national health insurance</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Double-blind method</keyword>
	<keyword>Randomized Controlled trial</keyword>
</DOC>